Tuesday, April 19, 2016

HCV Next - Pangenotypic Regimen: A Step Forward in HCV Treatment

"HCV Next" offers information on a range of topics, which include diagnosis, new combination therapies, side effects, drug/drug interaction, guidelines, practice management issues, to name a few.

The following articles appeared in the November print edition of HCV NEXT, provided online at Healio.

Table of Contents5 Questions
A Conversation with Robert J. Wong, MD, MS

Cover Story
Understanding the Rold of Statins in the DAA Era

The March Toward Elastography for Assessing Fibrosis in HCV

Guest Editorial
Pangenotypic Regimen: A Step Forward in HCV Treatment

In the Journals
HCV Prevalent in ED; Many Cases Missed by Birth-Cohort Testing

HCV Prevalent Among Former Incarcerated Individuals, Few Treated

Disparities in Access to Care for HCV Still Exist Despite New Regimens

Meeting News Coverage
PCP-Driven Care Safe, Effective for HCV

Researchers: HCV, HBV, Alcohol Use Associated with ESLD in Patients with HIV

Liver Fibrosis Decreases Cognitive Function in Women, Independent of HIV or HCV

Harvoni Effective for Patients with HIV, Acute HCV

Trend Watch
FDA Updates Olysio Label to Include East Asians with HCV Genotype 1

EMA Panel Recommends Approval of DAA Regimen for HCV with Cirrhosis

No comments:

Post a Comment